Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kyungsung University Industry Cooperation Foundation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is distributed to 1 distinct examiner and 1 distinct art unit. The university's current patent activity is focused on a single point of examination within the life sciences sector. Having only 1 pending office action suggests a highly selective or early-stage prosecution phase for the foundation's biotechnology research.
The busiest examiner is KOSTURKO, GEORGE W, who is currently managing 1 busiest examiner pending action. This represents the entirety of the foundation's active prosecution workload. Effective management of this portfolio requires a focused strategy addressing the specific concerns raised by this single examiner. Because the foundation is dealing with 1 distinct examiner and 1 distinct art unit, practitioners can focus on the specific technical standards of that unit to efficiently navigate the prosecution process and secure patent protection for the university's innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSTURKO, GEORGE W | 1 | 54.7% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272219 | COMPOSITION INCLUDING DECURSINOL AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SMOOTH MUSCLE CELL PROLIFERATIVE DISEASES | KOSTURKO, GEORGE W | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272219 | COMPOSITION INCLUDING DECURSINOL AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SMOOTH MUSCLE CELL PROLIFERATIVE DISEASES | KOSTURKO, GEORGE W | 23d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18272219 | COMPOSITION INCLUDING DECURSINOL AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SMOOTH MUSCLE CELL PROLIFERATIVE DISEASES | KOSTURKO, GEORGE W | 1621 | §102§103§112 | Non-Final OA | 23d | Pending | Jul 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial